DENTSPLY International Inc
How XRAY’s Performance Has Shaken Out over the Last Month
Dentsply Sirona stock witnessed a steady uptick in November, rising from $34.58 on November 6 to $37.78 on November 30.
What Does Dentsply’s Bottom-Line Trend Indicate?
Dentsply Sirona’s interest expense decreased marginally from $9.8 million in the third quarter of 2017 to $9.7 million in the third quarter.
Align Technology Traded at Its 52-Week High in September
Align Technology was trading at its 52-week high of $398.88 on September 25. The stock reported its 52-week low of $180.31 on September 28, 2017.
Wall Street Analysts Are Still Bullish on ALGN Stock
Align Technology (ALGN) stock hasn’t received any recommendation updates since the stock was upgraded by several analysts in July.
ALGN Stock Surpasses the S&P 500 Index’s Year-to-Date Gain
On September 28, Align Technology (ALGN) posted an ~74% increase year-to-date. In the same period, the S&P 500 Index has returned ~9%.
Dentsply Sirona’s Segments: Q2 2018 Performance
Since its second-quarter earnings release on July 7, Dentsply Sirona (XRAY) stock has plummeted ~20%.
Gauging Dentsply Sirona’s Valuation Trend and Recent Acquisitions
Dentsply Sirona (XRAY) has lowered its guidance for fiscal 2018. It expects adjusted EPS of $2–$2.15 compared to $2.55–$2.65 previously.
Top Losses: Cruise Operators Fell on June 5?
Carnival, which is a US-based cruise company and the world’s largest travel leisure company, was the S&P 500’s top loss on June 5.
Word on the Street: Recommendations and Target Prices on ALGN
Align Technology (ALGN) has reported a strong stock performance recently, with its stock price reaching a 52-week high on May 29.
Align Technology Reported a 52-Week High on May 29
Align Technology (ALGN) hosted its 2018 Investor Day on May 23. On the day, the company provided a variety of updates.
Align Technology: Analysts Raise Their Target Prices
On May 25, Berenberg increased its 12-month target price on Align Technology (ALGN) from $312 to $340.
Analysts Expect a Fall in Dentsply Sirona’s Adjusted Earnings
Dentsply Sirona accounts for ~0.29% of the total holdings of the Vanguard Mid-Cap ETF. It’s set to release its 1Q18 results on May 7.
Analysts Cut Their Targets for XRAY ahead of Its 1Q18 Results
Dentsply Sirona, one of the leading dental technology providers in the United States, will announce its 1Q18 earnings results on May 7.
Will Dentsply Sirona Stock Recover from Recent Declines?
On April 6, 2018, Dentsply Sirona (XRAY) ended at a closing price of $49.02 per share.
Why Barrington Research Cut Its Target Price on Dentsply Sirona
On March 27, 2018, Barrington Research reiterated its “buy” rating on Dentsply Sirona (XRAY) while reducing its target price on the stock from $70 to $69.
What Wall Street Analysts Recommend for Dentsply Sirona
Dentsply Sirona (XRAY), one of the leading dental technology providers in the United States, recently outlined a turnaround plan to recover from the company’s disappointing performance in recent years.
Dentsply Sirona to Acquire OraMetrix: What You Need to Know
On March 26, 2018, Dentsply Sirona (XRAY) announced its plans to acquire OraMetrix.
Reading Dentsply Sirona’s Guidance for 2018
For fiscal 2018, the company expects its sales to be in the range of $4.2 billion–$4.25 billion.
Why Is Dentsply Sirona So Confident That It Can Gain Market Share?
Although Dentsply Sirona has given a disappointing performance recently, the company is still confident that it can gain a higher market share going forward.
Here’s What Dentsply Sirona Has Planned for Its Margins
Dentsply Sirona has a new management team that is working toward a more successful integration because it delivered lower-than-expected synergies in 2017.
Why Innovation Matters to Dentsply Sirona—Now More Than Ever
Dentsply Sirona has an industry-leading R&D budget with more than 600 scientists and engineers. The company invests $125 million per year on R&D.
The Key Factors in Dentsply Sirona Sales Growth Plan
Dentsply Sirona (XRAY) has delivered lower merger synergies than the company had estimated. It also took an impairment charge during 4Q17.
Dentsply Sirona’s Top 5 Priorities for Executing a Strategic Business Turnaround
With the recent transition in leadership at Dentsply Sirona (XRAY), the new team has laid out a robust strategic growth plan.
Understanding Dentsply Sirona’s New Organizational Structure
In 4Q17, Dentsply Sirona (XRAY) started reporting its operations under two segments, after a shift to three segments in fiscal 3Q17.
Behind Dentsply Sirona’s Total Impairment Charges in 2017
Dentsply Sirona (XRAY) updated its estimates and assumptions during fiscal 2Q17 and underwent an annual impairment test of goodwill.
Reading Dentsply Sirona’s Recent Stock Performance
On March 13, 2018, Dentsply Sirona closed trading at a price of $57.80 per share. The stock registered its 52-week high of $68.98 on November 28, 2017.
Why Is Wall Street Still Upbeat on Dentsply Sirona’s Growth Potential in 2018?
Dentsply Sirona is a leading dental technology, equipment, and consumables provider in the US. But it has been going through some tough times.
Align Technology and Its SmileDirectClub Partnership
In 4Q17, Align Technology reported a sequential decline in its shipments of non-Invisalign SDC aligners to SDC.
Increased Penetration in Teen Market Is Still Align’s Focus
Every year, approximately 75% of Align Technology’s (ALGN) total orthodontic case starts are for teens.
Align’s iTero Scanner Was Strong Growth Driver in 2017
In 4Q17, Align Technology (ALGN) reported $57.1 million in revenues from its scanner and services business.
Align Technology’s Invisalign: Average Selling Price and Volumes
Increases in Align Technology’s (ALGN) Invisalign volumes and ASP were the major factors driving the company’s sales growth.
Align Technology: Analyst Ratings and Recommendations
Of the 12 investment research firms following ALGN stock, ten of them have given the stock “buy” or “strong buy” recommendations.
Wall Street Issues Majority ‘Buy’ Ratings on Align Technology
On December 29, 2017, according to 12 investment brokerage firms which were part of a Reuters survey, Align Technology stock has received a “buy” rating from 11 analysts.
Align Technology’s Customer Acquisition Strategy Driving Market Growth
In 3Q17, Align Technology trained nearly 1,000 doctors in China.
ALGN Terminates 3Shape TRIOS’s Invisalign Interoperability Contract
On December 20, 2017, Align Technology announced the termination of its Invisalign interoperability contract with 3Shape.
Align Technology’s Growth Prospects amid Increasing Competition
The Chinese market is Align Technology’s major growth driver. However, the company is starting to witness strong competition from startups focused on the clear aligners market.
Behind Align Technology’s Key Growth Driver in 2017
In 3Q17, Align Technology’s (ALGN) Invisalign case volumes shipped to doctors in international markets rose 47.4% on a YoY basis and 6.8% sequentially.
Developments in Dentsply Sirona’s Digital Dentistry Portfolio
On September 20, 2017, Dentsply Sirona (XRAY) announced an enhancement to its Galileos Implant software.
Dentsply Sirona’s Dental Sleep Medicine and a Recent Partnership
Dentsply Sirona (XRAY) and Zephyr Sleep Technologies have entered into a strategic partnership for the treatment of OSA (obstructive sleep apnea).
What Analysts Are Recommending for Dentsply Sirona
According to the recommendations of 15 brokerage firms, 60.0% (or nine) of them have rated Dentsply Sirona (XRAY) a “buy,” and 33.0% (or five) have rated it a “hold.”
Dentsply Sirona’s Newly Launched Cerec Zirconia Meso Block
In August 2017, Dentsply Sirona (XRAY) launched its Cerec Zirconia Meso Block for creating customized screw-retained crowns.
What Do Analysts Recommend for Dentsply Sirona?
Based on the recommendations of 16 brokerage companies, around 63% (or ten) of the analysts provided a “buy” recommendation for Dentsply Sirona.
Discussing Dentsply Sirona’s Recent Stock Performance
Dentsply Sirona (XRAY) closed at $55.30 on August 11, 2017. The company was trading at its 52-week low of $54.50 on the day.
Dentsply Sirona’s Technologies Segment Sales Declined in 2Q17
In 2Q17, Dentsply Sirona’s (XRAY) Technologies business contributed ~44% to the company’s total revenues and registered sales of ~$439 million.
Discussing Dentsply Sirona’s Updated 2017 Guidance
Dentsply Sirona made a downward revision to its fiscal 2017 guidance during the company’s 2Q17 earnings results announcement on August 9, 2017.
Dental and Healthcare Consumables Grew but Missed Expectations in 2Q17
In 2Q17, Dentsply Sirona’s (XRAY) Dental and Healthcare Consumables business contributed ~56% to the company’s total revenues and registered sales of ~$554 million.
Dentsply Sirona’s 2Q17 Results: Key Highlights
Dentsply Sirona (XRAY) reported its 2Q17 earnings on August 9. The company earned revenues of ~$992.7 million, registering a year-over-year decline of ~2.9%.
Align Technology Focuses on International Market Strategy
International market strategy In 2Q17, Align Technology (ALGN) reported 85,400 Invisalign case shipments in international markets, which is YoY (year-over-year) growth of ~37.4% and sequential growth of ~13.6%. This growth was mainly attributed to new customers in the EMEA (Europe, the Middle East, and Africa) and Asia-Pacific markets. If Align Technology continues to demonstrate solid […]
Analysts’ Recommendations for Align Technology in August 2017
Of the 13 analysts covering Align Technology in August 2017, eight rated the company a “strong buy,” and five rated it a “buy.”
Inside Align Technology’s Market Expansion Strategy
In 1Q17, Align Technology (ALGN) also witnessed a robust rise of around 45.2% in volumes of Invisalign sold in Asia-Pacific markets on a YoY basis.
Understanding Align Technology’s Growing Position in International Markets
In 1Q17, Align Technology (ALGN) witnessed an 11.4% sequential rise in the volume of Invisalign cases used by doctors in international markets.
These Are Align Technologies Key Demand Drivers in North America
In 1Q17, Align Technology (ALGN) has started selling its new product Invisalign Go in North America, which involves a few DSOs (dental service organizations).
Behind Align Technology’s North American Expectations for 2017
In 1Q17, Align Technology’s (ALGN) Invisalign sales volumes in North American markets rose YoY by 20.3% and QoQ by 8.3%.
Inside Align Technology’s Robust Revenue Growth Projection for 2017
For fiscal 2017, Align Technology (ALGN) expects its 2017 revenues to grow operationally in the range of 15%–25% YoY.
Why Align Technology’s Orthodontics Is a Solid Growth Opportunity in 2017
Align Technology (ALGN) is a medical device provider focused on malocclusion or teeth misalignment condition.
Align Technology versus Peers in June 2017: Analyst Recommendations
For 1Q17, Align Technology (ALGN) reported revenues close to $310.3 million, which represents YoY (year-over-year) growth of around 30.0%.
Dentsply Sirona’s New Growth Strategy to Accelerate Digital Dentistry Penetration
Dentsply Sirona is the largest dental equipment and solutions manufacturer in the United States. Digital dentistry is a megatrend in the market.
What Dragged Down Technology Business Sales in 1Q17?
Dentsply Sirona’s Technology segment sales Dentsply Sirona (XRAY) reported ~$900 million of revenues worldwide in 1Q17. Of that, ~$389 million was generated through Dentsply Sirona’s Technology segment, which contributed ~43.2% to Dentsply Sirona’s total revenues. On a constant currency basis, the Technology segment’s sales declined by approximately 8.1%. The segment’s sales were flat in Europe. The […]
How Dentsply Sirona’s Profitability Metrics Looked in 1Q17
Dentsply Sirona’s (XRAY) 1Q17 earnings and revenue failed to meet analysts’ estimates. The company reported a fall in its organic revenue.
Danaher Stock Jumps as EPS Grows 22.5% on Margin Expansion
Danaher (DHR) reported adjusted EPS of $0.87, which beat consensus estimates by $0.05. In growth terms, the adjusted EPS was 22.5% YoY.
Danaher to Declare Its First Earnings after Fortive Separation
Danaher Corporation (DHR), which became a diversified healthcare company after its restructuring actions, is slated to declare its 3Q16 earnings on October 20. The consensus Wall Street estimate is for Danaher to post adjusted EPS of $0.83 on sales of ~$4.1 billion.
Danaher’s Dental Unit Putting Shine on Teeth and Profits
Danaher’s Dental segment remained virtually unchanged when the company split its industrial businesses into the independent public company Fortive.
Danaher’s Dental Unit Enjoys These Competitive Advantages
Danaher’s Dental segment is a $2.7 billion business.
A Brief Look at the Technologies Segment Sales in 2Q16
In 2Q16, Dentsply Sirona’s leading position in the Digital Sensor category and rebound in the Lab business drove its Technologies segment sales.
What Are Analysts’ Recommendations for Dentsply Sirona?
According to a Bloomberg survey, 43% of the analysts gave Dentsply Sirona a “buy” rating and ~57% gave it a “hold” rating. It didn’t have any “sell” ratings.
Why Is Dentsply Sirona Acquiring MIS Implants?
Dentsply Sirona is acquiring MIS due to its established brand and broad portfolio of implants and related products.
A Look at Dentsply Sirona’s Technologies Segment
Dentsply Sirona’s (XRAY) technologies segment’s sales represented ~47% of the company’s total sales in 2015.
Exploring XRAY’s Dental and Healthcare Consumables Businesses
Dentsply Sirona’s consumables products segment is responsible for the manufacture, distribution, and sale of dental products.
A Brief Look at Dentsply Sirona’s Business Model
Dentsply Sirona (XRAY) offers a broad portfolio of dental equipment and consumables that have urological and surgical applications.
Introducing Dentsply Sirona, a Leading Dental Products Manufacturer
Dentsply Sirona (XRAY) is the largest manufacturer of dental equipment and technologies in the world. The company was formed in February 2016.
Chinese Trade Numbers Fall for 16th Straight Time: Effect on XLV
Chinese exports fell 25.4% on a year-over-year basis, and imports fell 13.8%, marking the 16th straight monthly decline. XLV fell 1.2% yesterday in response to the news.
Patterson Reports Fiscal 2Q16 Earnings, Drags Down Mid-Caps
Patterson Companies (PDCO) fell 6% on its lower-than-expected fiscal 2Q16 results. Investors were disappointed with increasing operating expenses.
How Does Patterson Companies Compare to Its Peers?
The respective PE ratios of Patterson Companies and peers Henry Schein, DENTSPLY International, and VCA are 23.6x, 27.1x, 31.5x, and 25.9x as of November 24.
How PerkinElmer Topped the XLV’s Mid-Cap Stocks
At the Stifel 2015 Healthcare Conference, PerkinElmer presented its current position as well as its future growth and strategies for different markets.
How Does Dentsply International Compare to Peers after 3Q15?
In this article, we’ll compare Dentsply against its peers and the ETFs that invest in Dentsply.
How Does Cantel Medical Compare to Its Peers?
Cantel Medical outperformed its peers based on the net profit margin, current ratio, PE ratio, and PBV ratio. It outperformed its ETFs based on the PBV ratio.
Cantel Medical’s Revenue and Income Rose in 4Q15
Cantel Medical reported net revenue of $151.255 million in 4Q15—a rise of 6.88% compared to the net revenue of $141.508 million in 3Q15.
Patterson Companies Was XLV’s Worst Performer
Patterson Companies was the worst performer within the Health Care Select Sector SPDR ETF (XLV) for the period between August 25 and August 31, with a return of -4.10%.